Global R&D Pipeline
My Favorite
Hot Targets:
CD19
Back
Total number of drugs
934
Phase II and later clinical stages
6.4%
Involving companies
819
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLO-501 | ALLO-501 | Universal CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD19 inhibitors | Cellectis SA | Institut de Recherches Intern Servier Cellectis, Inc. Les Laboratoires Servier SAS Allogene Therapeutics, Inc. Cellectis SA Institut Servier de Medecine Translationnelle SARL | Phase 2 | - | - | - | - | Advanced Therapy Medicinal Products（European Union） | - | - | - | - | ALLO-501 | - | - | detail > | |
| Cemacabtagene ansegedleucel | Cemacabtagene ansegedleucel | Universal CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD19 modulators | Cellectis SA | Allogene Therapeutics, Inc. Servier Pharmaceuticals LLC | Phase 2 | - | - | - | - | Fast Track（United States） Regenerative Medicine Advanced Therapy（United States） | - | - | - | - | Cemacabtagene ansegedleucel | - | - | detail > | |
| Anti-CD19 CAR T-cells(KK Women's and Children's Hospital) | Anti-CD19 CAR T-cells(KK Women's and Children's Hospital) | Universal CAR-T | - | CD19 inhibitors Immunologic cytotoxicity T lymphocyte replacements | KK Women's & Children's Hospital Pte Ltd. | KK Women's & Children's Hospital Pte Ltd. Singapore General Hospital Pte Ltd. | Phase 2 | - | - | - | - | - | - | - | - | - | Anti-CD19 CAR T-cells(KK Women's and Children's Hospital) | - | - | detail > | |
| Senl-1904B | Senl-1904B | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD19 inhibitors Gene transference T lymphocyte replacements | Hebei Senlangbio Biotechnology Co., Ltd. | Hebei Senlangbio Biotechnology Co., Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | Senl-1904B | - | - | detail > | |
| Anti-CD19 CAR-T cell therapy(Bellicum Pharmaceuticals, Inc.) | Anti-CD19 CAR-T cell therapy(Bellicum Pharmaceuticals, Inc.) | CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD19 modulators | Bellicum Pharmaceuticals, Inc. | Bellicum Pharmaceuticals, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | Anti-CD19 CAR-T cell therapy(Bellicum Pharmaceuticals, Inc.) | - | - | detail > | |
| CC-97540 | CC-97540 | Autologous CAR-T | Immune System Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Neoplasms Nervous System Diseases Hemic and Lymphatic Diseases Other Diseases | CD19 modulators Immunologic cytotoxicity T lymphocyte replacements | Juno Therapeutics, Inc. | Celgene Corp. Bristol Myers Squibb Co. Juno Therapeutics, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | CC-97540 | - | - | detail > | |
| Zamtocabtagene autoleucel | Zamtocabtagene autoleucel | Autologous CAR-T | Neoplasms Immune System Diseases Infectious Diseases Hemic and Lymphatic Diseases Other Diseases Nervous System Diseases Cardiovascular Diseases Congenital Disorders Skin and Musculoskeletal Diseases Urogenital Diseases | CD19 inhibitors CD20 inhibitors T lymphocyte replacements | Miltenyi Biomedicine GmbH | National Institute For Health & Care Research Miltenyi Biomedicine GmbH Miltenyi Biotec BV & Co. KG | Phase 2 | - | - | - | - | - | - | - | - | - | Zamtocabtagene autoleucel | - | - | detail > | |
| KYV-101 | KYV-101 | Autologous CAR-T | Neoplasms Immune System Diseases Nervous System Diseases Skin and Musculoskeletal Diseases Other Diseases Cardiovascular Diseases Urogenital Diseases Respiratory Diseases | CD19 inhibitors CD28 agonists T lymphocyte replacements | Kyverna Therapeutics, Inc. | Kyverna Therapeutics, Inc. Hannover Medical School | Phase 2/3 | - | - | - | - | Fast Track（United States） Orphan Drug（United States） Regenerative Medicine Advanced Therapy（United States） | - | - | - | - | KYV-101 | - | - | detail > | |
| CD19 CAR-T CELLS(Gaia Science) | CD19 CAR-T CELLS(Gaia Science) | Autologous CAR-T | Neoplasms Immune System Diseases Infectious Diseases Hemic and Lymphatic Diseases Other Diseases Skin and Musculoskeletal Diseases | CD19 inhibitors Gene transference | Gaia Science Pte Ltd. | University of Kebangsaan Malaysia Gaia Science Pte Ltd. | Phase 2/3 | - | - | - | - | - | - | - | - | - | CD19 CAR-T CELLS(Gaia Science) | - | - | detail > | |
| CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes(City of Hope National Medical Center) | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes(City of Hope National Medical Center) | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD19 inhibitors CD28 agonists EGFR modulators Cell replacements | City of Hope National Medical Center | City of Hope National Medical Center | Phase 2 | - | - | - | - | - | - | - | - | - | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes(City of Hope National Medical Center) | - | - | detail > |
Total 934 data
1
2
3
4
5
6
...
93
94
